Short description
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.
Description
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.The company's molecules specifically eradicate those cancer cells that cause drug resistance, enabling physicians to get personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients.
Last funding
Noaccess
Sign in for full access
Total funding
$$121212
Sign in for full access
Location
Zürich, Zurich, Switzerland, Europe
Founded on
January 1, 2017
Non-profit?
No
Acquired?
No
Employees count
1-10
Investors
Uh Ohhhh, Cannot Access, Cannot Access, Nopepepe, Uh Ohhhh
Sign in for full access
Founders
Emmanuel Savioz, Isaac Kobrin, Karl-Heinz Altmann, Stefanie Flückiger-Mangual, Wilhelm Krek